Allen Obie, Coombes Brandon J, Pazdernik Vanessa, Gisabella Barbara, Hartley Joshua, Biernacka Joanna M, Frye Mark A, Markota Matej, Pantazopoulos Harry
Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Mississippi.
Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
medRxiv. 2024 Apr 12:2024.04.11.24305678. doi: 10.1101/2024.04.11.24305678.
Many patients with bipolar disorder (BD) do not respond to or have difficulties tolerating lithium and/or other mood stabilizing agents. There is a need for personalized treatments based on biomarkers in guiding treatment options. The calcium voltage-gated channel CACNA1C is a promising candidate for developing personalized treatments. CACNA1C is implicated in BD by genome-wide association studies and several lines of evidence suggest that targeting L-type calcium channels could be an effective treatment strategy. However, before such individualized treatments can be pursued, biomarkers predicting treatment response need to be developed.
As a first step in testing the hypothesis that CACNA1C genotype is associated with serum levels of CACNA1C, we conducted ELISA measures on serum samples from 100 subjects with BD and 100 control subjects.
We observed significantly higher CACNA1C (p<0.01) protein levels in subjects with BD. The risk SNP (rs11062170) showed functional significance as subjects homozygous for the risk allele (CC) had significantly greater CACNA1C protein levels compared to subjects with one (p=0.013) or no copies (p=0.009). We observed higher somatostatin (SST) (p<0.003) protein levels and lower levels of the clock protein ARTNL (p<0.03) and stress signaling factor corticotrophin releasing hormone (CRH) (p<0.001) in BD. SST and PER2 protein levels were associated with both alcohol dependence and lithium response.
Our findings represent the first evidence for increased serum levels of CACNA1C in BD. Along with altered levels of SST, ARNTL, and CRH our findings suggest CACNA1C is associated with circadian rhythm and stress response disturbances in BD.
许多双相情感障碍(BD)患者对锂盐和/或其他心境稳定剂无反应或难以耐受。需要基于生物标志物的个性化治疗来指导治疗选择。钙电压门控通道CACNA1C是开发个性化治疗的一个有前景的候选者。全基因组关联研究表明CACNA1C与双相情感障碍有关,并且有几条证据表明靶向L型钙通道可能是一种有效的治疗策略。然而,在推行这种个体化治疗之前,需要开发预测治疗反应的生物标志物。
作为检验CACNA1C基因型与血清中CACNA1C水平相关这一假设的第一步,我们对100名双相情感障碍患者和100名对照者的血清样本进行了酶联免疫吸附测定(ELISA)。
我们观察到双相情感障碍患者的CACNA1C蛋白水平显著更高(p<0.01)。风险单核苷酸多态性(rs11062170)显示出功能意义,因为与有一个(p=0.013)或没有(p=0.009)该风险等位基因拷贝的受试者相比,风险等位基因纯合(CC)的受试者的CACNA1C蛋白水平显著更高。我们观察到双相情感障碍患者的生长抑素(SST)蛋白水平更高(p<0.003),而生物钟蛋白ARNTL(p<0.03)和应激信号因子促肾上腺皮质激素释放激素(CRH)(p<0.001)水平更低。SST和PER2蛋白水平与酒精依赖和锂反应均相关。
我们的研究结果首次证明双相情感障碍患者血清中CACNA1C水平升高。连同SST、ARNTL和CRH水平的改变,我们的研究结果表明CACNA1C与双相情感障碍的昼夜节律和应激反应紊乱有关。